Latest Breaking News On - Serono inc - Page 6 : comparemela.com

EMD Serono to Present Latest Research from Oncology Portfolio at ESMO 2023

EMD Serono to Present Latest Research from Oncology Portfolio at ESMO 2023

Evobrutinib, CNS-Penetrant BTKi, Has Shown Sustained Clinical Benefit Up to Five Years in People with RMS

EMD Serono Presents New MAVENCLAD® (Cladribine) Tablets Data Highlighting Sustained Reduction in NfLs and Benefit of Early Initiation

ROCKLAND, Mass., October 10, 2023 EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of new analyses from the MAVENCLAD® (cladribine) tablets MAGNIFY-MS study, which demonstrated that patients with relapsing multiple sclerosis (RMS) experienced sustained reduction in serum neurofilament light chain (NfL), indicating that MAVENCLAD reduced neuronal injury over two years. Additional data include two real-world evi

EMD Serono, Inc.: EMD Serono Launches New Collaboration with United Nations' Global Initiative on Ageing to Support Caregivers